

June 27, 2011



# Titan Pharmaceuticals to Present at 2011 BIO International Convention

**Tuesday, June 28, 2011, 9:45-10:00am EDT**

SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 06/27/11 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will make a corporate presentation providing an overview of the company during the BIO Business Forum at the 2011 BIO International Convention in Washington, DC, June 27-30, 2011. The presentation is scheduled for Tuesday, June 28, 2011, at 9:45-10:00am EDT (6:45-7:00am PDT). A copy of the presentation will be made available on the company's website.

## *About Titan Pharmaceuticals*

For information concerning Titan Pharmaceuticals, Inc., please visit the Company's website at [www.titanpharm.com](http://www.titanpharm.com).

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.

CONTACT:  
Titan Pharmaceuticals, Inc.  
Sunil Bhonsle  
650-244-4990  
President

Pure Communications  
Dan Budwick  
973-271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

Source: Titan Pharmaceuticals, Inc.